ICX-PRO

Drug Profile

ICX-PRO

Alternative Names: Cyzact; ICX PRO; ICXP 007

Latest Information Update: 03 Mar 2009

Price : $50

At a glance

  • Originator Intercytex
  • Class Fibroblast cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic foot ulcer; Varicose ulcer

Most Recent Events

  • 20 Feb 2009 Discontinued - Phase-II for Diabetic foot ulcer in United Kingdom (Topical)
  • 20 Feb 2009 Discontinued - Phase-III for Varicose ulcer in Canada (Topical)
  • 20 Feb 2009 Discontinued - Phase-III for Varicose ulcer in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top